Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

• Maximilian Merz,
• Hans Salwender,
• Mathias Haenel,
• Elias K. Mai,
• Uta Bertsch,
• Christina Kunz,
• Thomas Hielscher,
• Igor W. Blau,
• Christof Scheid,
• Dirk Hose,
• Anja Seckinger,
• Anna Jauch,
• Jens Hillengass,
• Marc S. Raab,
• Baerbel Schurich,
• Markus Munder,
• Peter Brossart,
• Christian Gerecke,
• Hans-Walter Lindemann,
• Matthias Zeis,
• Katja Weisel,
• Jan Duerig,
• Hartmut Goldschmidt

Affiliations

Maximilian Merz

University Hospital Heidelberg, Germany

Hans Salwender

Asklepios Hospital Hamburg Altona, Germany

Mathias Haenel

Klinikum Chemnitz, Germany

Elias K. Mai

University Hospital Heidelberg, Germany

Uta Bertsch

University Hospital Heidelberg, Germany;National Center for Tumor Diseases Heidelberg, Germany

Christina Kunz

German Cancer Research Center Heidelberg, Germany

Thomas Hielscher

German Cancer Research Center Heidelberg, Germany

Igor W. Blau

Charité Universitätsmedizin Berlin, Germany

Christof Scheid

University Hospital Cologne, Germany

Dirk Hose

University Hospital Heidelberg, Germany

Anja Seckinger

University Hospital Heidelberg, Germany

Anna Jauch

Institute of Human Genetics, University of Heidelberg, Germany

Jens Hillengass

University Hospital Heidelberg, Germany

Marc S. Raab

University Hospital Heidelberg, Germany

Baerbel Schurich

University Hospital Heidelberg, Germany

Markus Munder

University Medical Center Mainz, Germany

Peter Brossart

University Hospital Bonn, Germany

Christian Gerecke

Helios Hospital Berlin Buch, Germany

Hans-Walter Lindemann

Kath. Krankenhaus Hagen, Germany

Matthias Zeis

Asklepios Hospital St. Georg Hamburgy, Germany

Katja Weisel

University Hospital Tübingen, Germany

Jan Duerig

University Hospital Essen, Germany

Hartmut Goldschmidt

University Hospital Heidelberg, Germany;National Center for Tumor Diseases Heidelberg, Germany